Main clinical and hematologic characteristics at diagnosis in the training and validation cohorts
| Characteristic . | Training series . | Validation series . | . | ||
|---|---|---|---|---|---|
| Median (range) . | N (%) . | Median (range) . | N (%) . | P value* . | |
| Overall | 558 (100) | 274 (100) | |||
| Age, y | 73 (19-99) | 70 (41-98) | <.001† | ||
| ≤60 | 61 (11) | 55 (20) | <.001‡ | ||
| 61-70 | 135 (24) | 105 (38) | |||
| >70 | 362 (65) | 114 (42) | |||
| Gender | |||||
| Male | 377 (68) | 191 (70) | .532§ | ||
| Female | 181 (32) | 83 (30) | |||
| WHO subtype | |||||
| CMML-1 | 478 (86) | 218 (80) | .025‡ | ||
| CMML-2 | 80 (14) | 56 (20) | |||
| Hemoglobin level, g/dL | 11 (1-19) | 11 (2-17) | .224† | ||
| <10 g/dL | 190 (34) | 101 (37) | .479§ | ||
| ≥10 g/dL | 368 (66) | 173 (63) | |||
| Leukocyte count, × 109/L | 10 (1-156) | 13 (1-150) | .143† | ||
| <13 × 109/L (CMML-MD FAB subtype) | 338 (61) | 138 (50) | .005§ | ||
| ≥13 × 109/L (CMML-MP FAB subtype) | 220 (39) | 136 (50) | |||
| Platelet count, × 109/L | 123 (4-928) | 105 (1-979) | .091† | ||
| <100 × 109/L | 221 (40) | 132 (48) | .019§ | ||
| ≥100 × 109/L | 337 (60) | 142 (52) | |||
| Neutrophil count, × 109/L | 4.2 (0.1-73.9) | 6.3 (0.1-75.0) | .018† | ||
| <1.8 × 109/L | 103 (18) | 41 (15) | .218§ | ||
| ≥1.8 × 109/L | 455 (82) | 232 (85) | |||
| Monocyte count, × 109/L | 2.6 (1.1-40.9) | 6.4 (1.1-75.0) | <.001† | ||
| <3.0 × 109/L | 236 (57) | 128 (47) | .010§ | ||
| ≥3.0 × 109/L | 180 (43) | 146 (53) | |||
| Blasts in PB | |||||
| Absent | 367 (79) | 193 (70) | .013§ | ||
| Present | 100 (21) | 81 (30) | |||
| Blasts in BM, % | 3 (0-19) | 6 (0-19) | <.001† | ||
| <5 | 347 (62) | 116 (42) | <.001‡ | ||
| 5-9 | 138 (25) | 103 (38) | |||
| 10-19 | 73 (13) | 55 (20) | |||
| LDH level, U/L | 394 (104-2976) | 277 (97-7743) | <.001† | ||
| ≤480 UI/L | 242 (68) | 94 (46) | <.001§ | ||
| >480 UI/L | 115 (32) | 109 (54) | |||
| Ferritin level, mg/dL | 170 (6-4000) | 318 (58-2010) | .001† | ||
| ≤500 mg/dL | 173 (80) | 73 (63) | <.001§ | ||
| >500 mg/dL | 43 (20) | 43 (37) | |||
| RBC transfusion dependency|| | |||||
| No | 441 (79) | 205 (75) | .156§ | ||
| Yes | 116 (21) | 69 (25) | |||
| CMML-specific cytogenetic risk classification¶ | |||||
| Low | 429 (81) | 146 (63) | <.001‡ | ||
| Intermediate | 47 (9) | 41 (18) | |||
| High | 56 (10) | 45 (19) | |||
| Characteristic . | Training series . | Validation series . | . | ||
|---|---|---|---|---|---|
| Median (range) . | N (%) . | Median (range) . | N (%) . | P value* . | |
| Overall | 558 (100) | 274 (100) | |||
| Age, y | 73 (19-99) | 70 (41-98) | <.001† | ||
| ≤60 | 61 (11) | 55 (20) | <.001‡ | ||
| 61-70 | 135 (24) | 105 (38) | |||
| >70 | 362 (65) | 114 (42) | |||
| Gender | |||||
| Male | 377 (68) | 191 (70) | .532§ | ||
| Female | 181 (32) | 83 (30) | |||
| WHO subtype | |||||
| CMML-1 | 478 (86) | 218 (80) | .025‡ | ||
| CMML-2 | 80 (14) | 56 (20) | |||
| Hemoglobin level, g/dL | 11 (1-19) | 11 (2-17) | .224† | ||
| <10 g/dL | 190 (34) | 101 (37) | .479§ | ||
| ≥10 g/dL | 368 (66) | 173 (63) | |||
| Leukocyte count, × 109/L | 10 (1-156) | 13 (1-150) | .143† | ||
| <13 × 109/L (CMML-MD FAB subtype) | 338 (61) | 138 (50) | .005§ | ||
| ≥13 × 109/L (CMML-MP FAB subtype) | 220 (39) | 136 (50) | |||
| Platelet count, × 109/L | 123 (4-928) | 105 (1-979) | .091† | ||
| <100 × 109/L | 221 (40) | 132 (48) | .019§ | ||
| ≥100 × 109/L | 337 (60) | 142 (52) | |||
| Neutrophil count, × 109/L | 4.2 (0.1-73.9) | 6.3 (0.1-75.0) | .018† | ||
| <1.8 × 109/L | 103 (18) | 41 (15) | .218§ | ||
| ≥1.8 × 109/L | 455 (82) | 232 (85) | |||
| Monocyte count, × 109/L | 2.6 (1.1-40.9) | 6.4 (1.1-75.0) | <.001† | ||
| <3.0 × 109/L | 236 (57) | 128 (47) | .010§ | ||
| ≥3.0 × 109/L | 180 (43) | 146 (53) | |||
| Blasts in PB | |||||
| Absent | 367 (79) | 193 (70) | .013§ | ||
| Present | 100 (21) | 81 (30) | |||
| Blasts in BM, % | 3 (0-19) | 6 (0-19) | <.001† | ||
| <5 | 347 (62) | 116 (42) | <.001‡ | ||
| 5-9 | 138 (25) | 103 (38) | |||
| 10-19 | 73 (13) | 55 (20) | |||
| LDH level, U/L | 394 (104-2976) | 277 (97-7743) | <.001† | ||
| ≤480 UI/L | 242 (68) | 94 (46) | <.001§ | ||
| >480 UI/L | 115 (32) | 109 (54) | |||
| Ferritin level, mg/dL | 170 (6-4000) | 318 (58-2010) | .001† | ||
| ≤500 mg/dL | 173 (80) | 73 (63) | <.001§ | ||
| >500 mg/dL | 43 (20) | 43 (37) | |||
| RBC transfusion dependency|| | |||||
| No | 441 (79) | 205 (75) | .156§ | ||
| Yes | 116 (21) | 69 (25) | |||
| CMML-specific cytogenetic risk classification¶ | |||||
| Low | 429 (81) | 146 (63) | <.001‡ | ||
| Intermediate | 47 (9) | 41 (18) | |||
| High | 56 (10) | 45 (19) | |||
P value is the statistical comparison of the different characteristics in training and validation series.
Mann-Whitney U test.
χ2 test.
Fisher’s exact test.
RBC transfusion dependency was defined as having at least 1 RBC transfusion every 8 weeks over a period of 4 months.
CMML-specific cytogenetic risk classification: low, normal and isolated –Y; intermediate, other abnormalities; and high, trisomy 8, complex karyotype (≥3 abnormalities), and abnormalities of chromosome 7.